161 related articles for article (PubMed ID: 32071050)
1. An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment.
Francis J; Barnes KI; Workman L; Kredo T; Vestergaard LS; Hoglund RM; Byakika-Kibwika P; Lamorde M; Walimbwa SI; Chijioke-Nwauche I; Sutherland CJ; Merry C; Scarsi KK; Nyagonde N; Lemnge MM; Khoo SH; Bygbjerg IC; Parikh S; Aweeka FT; Tarning J; Denti P
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071050
[TBL] [Abstract][Full Text] [Related]
2. The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients.
Kredo T; Mauff K; Workman L; Van der Walt JS; Wiesner L; Smith PJ; Maartens G; Cohen K; Barnes KI
BMC Infect Dis; 2016 Jan; 16():30. PubMed ID: 26818566
[TBL] [Abstract][Full Text] [Related]
3. Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy.
Banda CG; Dzinjalamala F; Mukaka M; Mallewa J; Maiden V; Terlouw DJ; Lalloo DG; Khoo SH; Mwapasa V
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150465
[TBL] [Abstract][Full Text] [Related]
4. Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.
Hughes E; Mwebaza N; Huang L; Kajubi R; Nguyen V; Nyunt MM; Orukan F; Mwima MW; Parikh S; Aweeka F
J Acquir Immune Defic Syndr; 2020 Feb; 83(2):140-147. PubMed ID: 31929402
[TBL] [Abstract][Full Text] [Related]
5. Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.
Byakika-Kibwika P; Lamorde M; Okaba-Kayom V; Mayanja-Kizza H; Katabira E; Hanpithakpong W; Pakker N; Dorlo TP; Tarning J; Lindegardh N; de Vries PJ; Back D; Khoo S; Merry C
J Antimicrob Chemother; 2012 May; 67(5):1217-23. PubMed ID: 22316571
[TBL] [Abstract][Full Text] [Related]
6. Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection.
Adegbola A; Abutaima R; Olagunju A; Ijarotimi O; Siccardi M; Owen A; Soyinka J; Bolaji O
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30082286
[TBL] [Abstract][Full Text] [Related]
7. Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.
Kredo T; Mauff K; Van der Walt JS; Wiesner L; Maartens G; Cohen K; Smith P; Barnes KI
Antimicrob Agents Chemother; 2011 Dec; 55(12):5616-23. PubMed ID: 21947399
[TBL] [Abstract][Full Text] [Related]
8. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
Byakika-Kibwika P; Lamorde M; Mayito J; Nabukeera L; Namakula R; Mayanja-Kizza H; Katabira E; Ntale M; Pakker N; Ryan M; Hanpithakpong W; Tarning J; Lindegardh N; de Vries PJ; Khoo S; Back D; Merry C
J Antimicrob Chemother; 2012 Sep; 67(9):2213-21. PubMed ID: 22687893
[TBL] [Abstract][Full Text] [Related]
9. Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications.
Hoglund RM; Byakika-Kibwika P; Lamorde M; Merry C; Ashton M; Hanpithakpong W; Day NP; White NJ; Äbelö A; Tarning J
Br J Clin Pharmacol; 2015 Apr; 79(4):636-49. PubMed ID: 25297720
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.
Achan J; Kakuru A; Ikilezi G; Ruel T; Clark TD; Nsanzabana C; Charlebois E; Aweeka F; Dorsey G; Rosenthal PJ; Havlir D; Kamya MR
N Engl J Med; 2012 Nov; 367(22):2110-8. PubMed ID: 23190222
[TBL] [Abstract][Full Text] [Related]
11. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.
Parikh S; Kajubi R; Huang L; Ssebuliba J; Kiconco S; Gao Q; Li F; Were M; Kakuru A; Achan J; Mwebaza N; Aweeka FT
Clin Infect Dis; 2016 Aug; 63(3):414-22. PubMed ID: 27143666
[TBL] [Abstract][Full Text] [Related]
12. Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria.
Usman SO; Oreagba IA; Akinyede AA; Agbaje EO; Akinleye MO; Onwujuobi AG; Ken-Owotor C; Adeuja O; Ogunfowokan T; Kogbe S; Owolabi ET; Adeniji H; Busari AW; Hassan OO; Abideen G; Akanmu AS
J Pharmacol Sci; 2020 Nov; 144(3):95-101. PubMed ID: 32921396
[TBL] [Abstract][Full Text] [Related]
13. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM
Malar J; 2015 Apr; 14():179. PubMed ID: 25906774
[TBL] [Abstract][Full Text] [Related]
14. Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.
Kay K; Goodwin J; Ehrlich H; Ou J; Freeman T; Wang K; Li F; Wade M; French J; Huang L; Aweeka F; Mwebaza N; Kajubi R; Riggs M; Ruiz-Garcia A; Parikh S
Clin Pharmacol Ther; 2023 Mar; 113(3):660-669. PubMed ID: 36260349
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
Kakuda TN; DeMasi R; van Delft Y; Mohammed P
HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the effects of atazanavir-ritonavir on the pharmacokinetics of lumefantrine in patients living with HIV in Lagos University Teaching Hospital, South-Western Nigeria.
Usman SO; Oreagba IA; Kadri MR; Adewumi OO; Akinyede A; Agbaje EO; Abideen G; Busari AA; Hassan OO; Akinleye MO; Akanmu AS
Eur J Clin Pharmacol; 2021 Sep; 77(9):1341-1348. PubMed ID: 33755736
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?
Abdullahi ST; Olagunju A; Soyinka JO; Bolarinwa RA; Olarewaju OJ; Bakare-Odunola MT; Owen A; Khoo S
Br J Clin Pharmacol; 2019 Mar; 85(3):540-550. PubMed ID: 30471138
[TBL] [Abstract][Full Text] [Related]
18. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.
German P; Parikh S; Lawrence J; Dorsey G; Rosenthal PJ; Havlir D; Charlebois E; Hanpithakpong W; Lindegardh N; Aweeka FT
J Acquir Immune Defic Syndr; 2009 Aug; 51(4):424-9. PubMed ID: 19506482
[TBL] [Abstract][Full Text] [Related]
19. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
Maganda BA; Minzi OM; Ngaimisi E; Kamuhabwa AA; Aklillu E
Pharmacogenomics J; 2016 Feb; 16(1):88-95. PubMed ID: 25963334
[TBL] [Abstract][Full Text] [Related]
20. Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: A case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin.
Olafuyi O; Coleman M; Badhan RKS
Eur J Pharm Sci; 2017 Aug; 106():20-33. PubMed ID: 28546104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
